What is the recommended pneumococcal vaccination schedule for infants, including routine PCV13 dosing, catch‑up if doses are missed, and additional PPSV23 for high‑risk infants?

Pneumococcal Vaccination for Infants

All healthy infants should receive PCV13 as a 4-dose series at 2,4,6, and 12–15 months of age, with the first dose starting as early as 6 weeks but typically at 2 months. 1, 2

Routine Schedule for Healthy Infants

The standard vaccination regimen consists of:

• Primary series: 3 doses at 2,4, and 6 months of age
  • Doses should be spaced approximately 8 weeks apart (minimum interval: 4 weeks)
• Booster dose: Fourth dose at 12–15 months of age
  • Must be given at least 8 weeks after the third dose 1, 2

Important note for premature infants: For infants born at <37 weeks' gestation who are medically stable, administer PCV13 at the recommended chronologic age (not corrected age) concurrent with other routine vaccinations. 1

Catch-Up Schedules for Missed Doses

The number of doses required depends on the age when vaccination begins:

Infants 7–11 Months (Starting Late)

• 3 total doses needed:
  • First 2 doses: minimum 4 weeks apart
  • Third dose: at 12–15 months, at least 8 weeks after the second dose 1

Children 12–23 Months (Unvaccinated)

• 2 doses needed: minimum 8 weeks apart 1

Children 24–59 Months (Healthy, Unvaccinated)

• 1 single dose 1

Critical principle: Interruption of the vaccination schedule does not require restarting the entire series or adding extra doses—simply continue where you left off. 1

High-Risk Infants Requiring Additional Vaccination

Children aged 24–71 months with underlying medical conditions that increase pneumococcal disease risk require 2 doses of PCV13 (minimum 8 weeks apart), regardless of previous vaccination status. 1

PPSV23 for High-Risk Children

For high-risk children who have completed their PCV13 series, administer PPSV23 at ≥24 months of age, at least 8 weeks after the final PCV13 dose. 1

High-risk conditions include:

• Immunocompromising conditions (HIV infection, malignancy, transplant recipients)
• Anatomic or functional asplenia (including sickle cell disease)
• Chronic heart disease, chronic lung disease, diabetes mellitus
• Cerebrospinal fluid leaks or cochlear implants
• Chronic renal failure or nephrotic syndrome 1

Important caveat: Limited data exist on PPSV23 effectiveness in children who received PCV13, and there are theoretical concerns about hyporesponsiveness (reduced antibody response to subsequent pneumococcal antigens) when PPSV23 is given. However, the recommendation stands for high-risk children due to broader serotype coverage. 1

Transitioning from PCV7 to PCV13

For children who received any doses of the older PCV7:

• Children <24 months: Complete the series with PCV13
• Children 12–23 months who received 3 doses of PCV7 before 12 months: Give 1 dose of PCV13 at least 8 weeks after the most recent PCV7 dose 1
• Healthy children 14–59 months who completed PCV7 series: Give 1 supplemental dose of PCV13 1

Key Clinical Pitfalls to Avoid

1. Don't delay the first dose unnecessarily: While 2 months is standard, vaccination can begin as early as 6 weeks if needed 2

2. Don't use corrected age for premature infants: Use chronologic age for scheduling 1

3. Don't restart the series for missed doses: Continue from where the child left off 1

4. Don't give PPSV23 before completing PCV13 in high-risk children: Always complete PCV13 series first, then add PPSV23 at least 8 weeks later 1

5. Don't forget high-risk children aged 24–71 months need 2 PCV13 doses (not just 1 like healthy children) if they have incomplete vaccination history 1

The evidence base for these recommendations comes primarily from ACIP guidelines 1 and FDA labeling 2, representing the highest-quality guidance available for pneumococcal vaccination in infants.